Sovaldi
E411074
Sovaldi is a breakthrough antiviral medication used to treat chronic hepatitis C by directly inhibiting the virus’s replication.
All labels observed (3)
| Label | Occurrences |
|---|---|
| sofosbuvir | 2 |
| Sofosbuvir | 1 |
| Sovaldi canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T4050931 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Sovaldi Context triple: [Gilead Sciences, product, Sovaldi]
-
A.
Harvoni
Harvoni is a prescription antiviral medication used to treat chronic hepatitis C virus (HCV) infection.
-
B.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
C.
Truvada
Truvada is a prescription antiretroviral medication widely used both to treat HIV infection and as pre-exposure prophylaxis (PrEP) to help prevent HIV in high-risk individuals.
-
D.
Descovy
Descovy is a prescription antiretroviral medication from Gilead Sciences used for the treatment and prevention (PrEP) of HIV-1 infection.
-
E.
velpatasvir
Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Sovaldi Target entity description: Sovaldi is a breakthrough antiviral medication used to treat chronic hepatitis C by directly inhibiting the virus’s replication.
-
A.
Harvoni
Harvoni is a prescription antiviral medication used to treat chronic hepatitis C virus (HCV) infection.
-
B.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
C.
Truvada
Truvada is a prescription antiretroviral medication widely used both to treat HIV infection and as pre-exposure prophylaxis (PrEP) to help prevent HIV in high-risk individuals.
-
D.
Descovy
Descovy is a prescription antiretroviral medication from Gilead Sciences used for the treatment and prevention (PrEP) of HIV-1 infection.
-
E.
velpatasvir
Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
antiviral medication
ⓘ
direct-acting antiviral ⓘ hepatitis C drug ⓘ |
| approvedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| approvedIn |
European Union
ⓘ
United States ⓘ
linked to:
United States of America
|
| belongsToClass | nucleotide analog polymerase inhibitors ⓘ |
| boxedWarning | risk of hepatitis B virus reactivation in coinfected patients ⓘ |
| commonAdverseEffect |
fatigue
ⓘ
headache ⓘ insomnia ⓘ nausea ⓘ |
| contraindicatedWith | amiodarone (relative contraindication due to bradycardia risk) ⓘ |
| developedBy |
Gilead Sciences
ⓘ
linked to:
Gilead Sciences (board member)
|
| dosageForm | film-coated tablet ⓘ |
| eliminationHalfLife |
approximately 0.4 hours for sofosbuvir
ⓘ
approximately 27 hours for main metabolite GS-331007 ⓘ |
| FDAApprovalDate | 2013-12-06 ⓘ |
| hasActiveIngredient | sofosbuvir ⓘ |
| hasATCCode | J05AX15 ⓘ |
| hasBreakthroughDesignation | yes (for certain HCV indications) ⓘ |
| hasGenericName |
sofosbuvir
ⓘ
linked to:
Sovaldi
|
| hasMechanismOfAction | NS5B RNA-dependent RNA polymerase inhibition ⓘ |
| indicatedFor |
treatment of chronic hepatitis C in adults
ⓘ
treatment of chronic hepatitis C in pediatric patients 3 years and older ⓘ |
| inhibits |
HCV NS5B polymerase
ⓘ
linked to:
HCV NS5B RNA-dependent RNA polymerase
|
| isFirstInClass | one of the first highly effective oral DAAs for HCV ⓘ |
| isProdrugOf | sofosbuvir triphosphate ⓘ |
| marketedBy |
Gilead Sciences
ⓘ
linked to:
Gilead Sciences (board member)
|
| metabolizedTo | GS-461203 (active triphosphate) ⓘ |
| patentHolder |
Gilead Sciences
ⓘ
linked to:
Gilead Sciences (board member)
|
| pregnancyCategoryUS | B ⓘ |
| requiresMonitoring |
HBV coinfection status
ⓘ
hepatic function ⓘ |
| routeOfAdministration | oral ⓘ |
| seriousAdverseEffect | severe bradycardia with amiodarone coadministration ⓘ |
| takenWithFood | may be taken with or without food ⓘ |
| treats |
chronic hepatitis C virus infection
ⓘ
hepatitis C genotype 1 ⓘ hepatitis C genotype 2 ⓘ hepatitis C genotype 3 ⓘ hepatitis C genotype 4 ⓘ hepatitis C genotype 5 ⓘ hepatitis C genotype 6 ⓘ |
| typicalDose | 400 mg once daily in adults ⓘ |
| usedInCombinationWith |
daclatasvir
ⓘ
ledipasvir ⓘ peginterferon alfa ⓘ ribavirin ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Sovaldi Description of subject: Sovaldi is a breakthrough antiviral medication used to treat chronic hepatitis C by directly inhibiting the virus’s replication.
Referenced by (4)
Full triples — surface form annotated when it differs from this entity's canonical label.